Anti-PD-1 immunotherapy is a type of cancer treatment that blocks the interaction between programmed cell death protein 1 (PD-1) and its ligands (PD-L1 and PD-L2), thereby enhancing T-cell anti-tumor activity. This evidence concerns the gene PDCD1 and neoplasm.